Chris Decker

President & CEO | CDISC

Chris Decker is President and CEO of CDISC. Widely recognized in the industry, Chris has decades of experience leveraging technology and standards to optimize processes and help industry drive innovation forward. He has extensive experience in executive roles across software development, clinical research, and consulting and his 20-year engagement with CDISC includes roles as a volunteer, implementer, and board member. Chris is passionate about leading CDISC towards a technology-based standards future and expanding the organization's global impact in clinical research standards.

Peter Krusche

Global Head, AI & Data Engineering | Novartis

Peter Krusche leads the AI & Data Engineering team within the Development Advanced Quantitative Sciences organization at Novartis. The team applies advanced computational methods and artificial intelligence to accelerate research and streamline the collection, integration, and analysis of data from clinical trials in regulated GxP environments, spanning clinical, imaging, omics, and other data modalities. With a background in computer science and more than 25 years of industry experience, Peter has worked across a broad range of disciplines, including artificial intelligence, bioinformatics, next-generation sequencing, systems biology, and software engineering.

Michael Rimler

Open Source Technologies Director | PHUSE

Michael currently serves as Head of Flu/Covid Programming within GSK Vaccines and Open Source Technologies Director at PHUSE. He has over 15 years of experience in the pharmaceutical industry, providing technical, analytical, and leadership support to clinical reporting teams. Prior to joining GSK, Michael worked for a number of CROs and, in a previous life, served on the faculty of Xavier University as an Assistant Professor of Economics. Michael is passionate about easing pain points of conventional clinical reporting workflows, including exploring opportunities to capitalize on open-source and AI solutions, as well as implementation of agile ways of working. In 2019, he launched the GSK Clinical Programming’s R Adoption initiative and is a co-founder of the pharmaverse.

Eric Nantz

Senior Director, Statistical Innovation Center | Eli Lilly and Company

Eric Nantz is a senior director within the Statistical Innovation Center at Eli Lilly and Company. Eric has over 17 years of experience across multiple roles as a clinical trial statistician and statistical software engineer creating analytical pipelines and capabilities of advanced statistical methodologies for clinical design used in multiple phases of development. In addition to his role at Eli Lilly, Eric is a founding member and co-organizer of the R/Pharma organization, as well as member of the R-Consortium working groups addressing the use of R and other open-source technology in clinical trial submissions. Outside of his day job, Eric hosts multiple podcasts dedicated to showcasing the innovations of R including the R-Podcast, Shiny Developer Series, and R Weekly Highlights.

Will Landau

Statistician & Developer | Eli Lilly and Company

Will Landau is a statistician and developer at Eli Lilly and Company, where he builds tools and methods for clinical statisticians. His work focuses on software and computational infrastructure for clinical trial simulation and statistical modeling, as well as open-source efforts such as the targets R package and the R-multiverse dual repository. He is active in rOpenSci, Openstatsware, and the R Consortium. Will earned his PhD from Iowa State University in 2016, where his research applied Bayesian methods and GPU computing to genomic data analysis.

Ben O'Brien

Head of Commercialisation | ERA Sciences

Ben O’Brien is an AI compliance expert and Head of Commercialisation at Phanero, the life science industry’s first dedicated GxP AI management system. Grounded in chemistry with cross-functional experience spanning Quality, Validation, and IT within life sciences, Ben specializes in translating strict regulatory standards into scalable, audit-ready AI operations. He works alongside C-suite leaders and technical specialists alike to establish robust AI governance, streamline GxP validation, and demonstrate measurable AI maturity.

Marcin Dubel

Head of Technology | Appsilon

Head of Technology at Appsilon, responsible for engineering excellence and AI innovation, including the Mediforce implementation, and for the quality of the solutions delivered to enterprise clients. Marcin brings 10+ years of hands-on software engineering experience supporting that leadership. A recognized Shiny expert and winner of the 2021 RStudio Shiny Contest Grand Prize, he has deep expertise in R, Shiny, and data visualization, with an academic background in statistics and software engineering. As a member of the Pharmaverse Council, he focuses on the Future Focus pillar: exploring how AI and emerging technologies can fill gaps in open-source tooling for clinical trials. He speaks regularly at conferences on Shiny, AI adoption, and building analytical tools that are both powerful and intuitive.

Pascal Bouquet

Founder & Managing Director, Senior Advisor | HealthTech Partners 42

Pascal Bouquet is a seasoned technologist with over 30 years of experience driving data and digital transformation across global life sciences organizations, including a decade at Novartis as CTO of the data42 initiative. He is the Founder of HealthTechPartners 42, a network of 50 senior experts in clinical development, a senior advisor on the application of AI in clinical development, and a member of the CDISC 360i Advisory Group, bringing together leading heads of standards from across the industry. Pascal supports multiple organizations in designing and deploying data-driven, AI-enabled platforms, with deep expertise in data strategy, artificial intelligence, and the end-to-end transformation of pharmaceutical R&D.

Dr. Gabriel Eichler

Partner | HealthTech Partners 42

Dr. Gabriel Eichler is a partner at HealthTech Partners 42 and Founder/Managing Director of Oak Health Partners AG, a boutique strategy and advisory firm focused on Data & AI in Life Sciences R&D. He previously served as VP and Head of Data for Novartis's Data42 initiative, leading a 70+ person team that built the data and analytics infrastructure now used by over 2,500 users across 1,000+ R&D projects, following earlier roles at Harvard Business School's Kraft Precision Medicine Accelerator, GNS Healthcare, PatientsLikeMe, and McKinsey & Company. He holds a PhD in Bioinformatics (Boston University/NCI) and a BSE in Computer Science (University of Pennsylvania), and has authored 40+ publications and delivered over 100 talks on life science AI and precision medicine.

Dr. David Foster

VP AI & Data Science | eClinical Solutions

Dr. David Foster is VP of AI and Data Science at eClinical Solutions, where he leads AI strategy and development for the elluminate Clinical Data Intelligence Platform, bringing agentic AI to clinical data so sponsors move from data to insight faster. He previously served as VP of AI at Aiwyn, building AI into its platform for modern accounting firms, and eight years as VP of Technology and AI at Metabolon, the world's leading metabolomics company. He holds a PhD in Physics (University of Calgary), focused on systems biology, and a BS in Physics from Duke University.

Magalie Wasem Treguer

Founder & Managing Partner | PharmaLaw Solutions

Magalie Wasem Treguer is an international life sciences lawyer with more than 25 years of experience advising pharmaceutical, biotechnology and medical device companies on complex legal, regulatory, compliance and privacy matters. She is the founder and Managing Partner of PharmaLaw Solutions, a specialist consultancy providing tailored advice to the life sciences industry. Magalie has particular expertise at the intersection of law, regulation and the development and commercialisation of healthcare products. Her practice encompasses clinical research and R&D, regulatory and pharmacovigilance matters, healthcare compliance, data protection and privacy, as well as emerging digital and artificial intelligence regulation. She also brings extensive corporate, transactional and commercial experience. Prior to founding PharmaLaw Solutions in 2015, Magalie spent more than a decade with Biogen, where she held several senior international legal and compliance positions. Magalie began her career in the M&A practice of Freshfields Bruckhaus Deringer in Paris, as a member of the Paris bar advising on cross-border corporate transactions, including in the life sciences sector. Most recently, she obtained a Master in Law and Artificial Intelligence. She regularly publishes and speaks on life sciences legal and regulatory developments and teaches as a guest lecturer. She is also the founder of the Life Sciences Senior Counsel Network, which brings together senior legal, compliance and privacy professionals from across the industry.

Anna De Feo

Novartis

Anna De Feo, AQS Change Management Director Transformation leader with 20+ years of experience progressing from learning and development into enterprise change management, organizational capability and technology transformation. Led global transformation initiatives across Novartis, Sandoz and MSD, partnering with executive leadership teams to drive workforce adoption, organizational effectiveness, leadership capability and business readiness in complex multinational environments. Experienced leading organizational change during major enterprise initiatives including digital transformation, scientific computing modernization and the Sandoz/Novartis separation.

Sarah Banks

togetherwethrive.ai

Sarah Banks is Co-Founder of THRIVE, a people-first change and communications consultancy helping organizations close the “last mile” between transformation strategy, adoption and business impact. Drawing on more than 15 years’ in-house experience in global pharma, Sarah works at the intersection of AI, digital transformation, organizational change and communications. Her focus is helping leaders turn technology deployment into meaningful change — redesigning how work gets done and building the clarity, capability and confidence people need to adopt new ways of working.

Andre Verissimo

Senior Engineer | Appsilon

André is a senior engineer at Appsilon developing tools to better understand and interact with data. André holds a Ph.D. in Computer Engineering specializing in exploring new survival models for omics cancer data that use network topology to improve accuracy and interpretability. At Appsilon he delivers enterprise-ready dashboards, is a teal core developer and contributes to R Consortium submissions working group.